Acadia Pharmaceuticals rockets higher after it announces it has ended a phase 3 trial of its dementia-related psychosis treatment, pimavanserin, on better-than-expected results.
Let's see what the charts suggest.
Lilly acquired the drug as part of its $8 billion acquisition of Loxo Oncology.
Let's check out the charts to get a sense of where prices could be headed.
Purdue, owned by the Sackler family, is already deep in negotiations with officials across the country to resolve thousands of lawsuits alleging the pharma giant helped fuel the opioid addiction crisis.
In its pending settlement agreement with Cuyahoga and Summit counties, Mallinckrodt has agreed to pay $24 million cash and $6 million in generic products, including products for addiction treatment.
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
During a talk with TheStreet, Cloudera interim CEO Marty Cole argued that his company's merger with rival Hortonworks gives it the resources to develop an end-to-end platform that neither company could have built on its own.
Shares of drugmaker Mallinckrodt plunge on a report the company is considering filing for bankruptcy as a way of dealing with its opioid-related legal liabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.